Cargando…

Rationale for adjuvant measures in musculoskeletal diseases

Detalles Bibliográficos
Autor principal:	Gast, Ulf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667109/ http://dx.doi.org/10.1186/1471-2474-14-S2-O10

Ejemplares similares

Successful approaches in genetics of musculoskeletal diseases
por: Brown, MA
Publicado: (2005)

Targeting the parasite in the mosquito: rationale and practicality
por: Sinden, Robert E, et al.
Publicado: (2012)

Cellular therapies in musculoskeletal diseases: synovial-derived mesenchymal stem cells
por: Luyten, F
Publicado: (2003)

The cardiac atlas project: rationale, design and preliminary results
por: Medrano-Gracia, Pau, et al.
Publicado: (2011)

Health needs assessment of musculoskeletal conditions: an international bone and joint burden of disease study
por: Khaltaev, N, et al.
Publicado: (2004)

Design and rationale of the MR-INFORM study: stress perfusion MRI to guide the management of patients with stable coronary artery disease
por: Hussain, Shazia T, et al.
Publicado: (2012)

Nitrate-induced tolerance, toxicity and preconditioning: a rationale for reconsidering the use of these drugs
por: Parker, John D, et al.
Publicado: (2009)

A systems approach reveals that the musculoskeletal tissues development and homeostasis network
por: Asahara, Hiroshi
Publicado: (2012)

The development of a new service for the management of Non-inflammatory Musculoskeletal Pain
por: Bhagat, S, et al.
Publicado: (2011)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Frequent discordance between clinical and musculoskeletal ultrasound examinations of foot disease in juvenile idiopathic arthritis observed in the multidisciplinary setting
por: Hendry, Gordon J, et al.
Publicado: (2011)

MRgFUS new applications in musculoskeletal pathology: a miscellaneous case review
por: Bazzocchi, Alberto, et al.
Publicado: (2015)

Adjuvant therapy of HER2(+ )breast cancer
por: Winer, EP
Publicado: (2009)

Controversies in hormonal adjuvant therapy for premenopausal patients
por: Howell, A
Publicado: (2009)

Controversies in the hormonal adjuvant therapy of postmenopausal patients
por: Dowsett, M
Publicado: (2009)

Bisphosphonates in the adjuvant treatment of early breast cancer
por: Gnant, M
Publicado: (2009)

Musculoskeletal ultrasound versus magnetic resonance in supporting clinical management of juvenile idiopathic arthritis
por: Lanni, Stefano, et al.
Publicado: (2014)

Adjuvant therapy in colorectal cancer – studies of the FOGT group
por: Staib, Ludger, et al.
Publicado: (2010)

Adjuvant therapy after preoperative treatment for breast cancer
por: Ciruelos, E
Publicado: (2009)

Use of the anti HER-2/neu antibody Herceptin in the treatment of human breast cancer: biological rationale and clinical results
por: Slamon, DJ
Publicado: (2000)

Assessing the burden of musculoskeletal conditions: a joint World Health Organization–Bone and Joint Decade project
por: Khaltaev, N, et al.
Publicado: (2003)

Adjuvant chemotherapy for operable breast cancer: old vs new schema
por: Valagussa, P, et al.
Publicado: (2005)

Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics
por: Harvey, Christopher, et al.
Publicado: (2015)

PReS-FINAL-2004: Musculoskeletal pain in schoolchildren across puberty: a 3-year follow-up study
por: Sperotto, F, et al.
Publicado: (2013)

Clinical spectrum of post-chikungunya rheumatic musculoskeletal disorders and use of disease-modifying antirheumatic drugs to treat the chronic inflammatory entities: 6-year experience from Reunion Island
por: Javelle, Emilie, et al.
Publicado: (2014)

P173 PK PD rationale and efficacy of isavuconazole treatment after failure of amphotericin B and posaconazole for COVID-19 associated cranial Mucormycosis
por: Soman, Rajeev, et al.
Publicado: (2022)

Monophosphoryl Lipid a as an adjuvant for immune therapy? A detailed in vitro comparison to LPS
por: Schülke, Stefan, et al.
Publicado: (2014)

Increased immunogenicity of HIV vaccination with constant-current electroporation and molecular adjuvants in mice and rhesus macaques
por: Hirao, Lauren, et al.
Publicado: (2006)

18. Resident Perception of Gender Disparities in Plastic Surgery Training
por: Attaluri, Pradeep, et al.
Publicado: (2022)

Radically resected node-negative squamous cell carcinoma of thoracic esophagus: recurrence pattern and indication for adjuvant therapy
por: Fang, W, et al.
Publicado: (2013)

Dietary triglycerides profoundly affect oral sensitization to peanut protein in an adjuvant-free mouse model of peanut allergy
por: Eckhardt, Erik, et al.
Publicado: (2011)

Infiltration of dendritic cells and antigen uptake in the muscle after injection of HIV-1 Env gp120 in adjuvant
por: Liang, F, et al.
Publicado: (2012)

Classical versus new prognostic factors for adjuvant treatment selection based on line software to estimate risk and benefit
por: Ravdin, PM
Publicado: (2005)

Ultrasound elastography as an adjuvant to conventional ultrasound in the preoperative assessment of axillary lymph nodes in suspected breast cancer: a pilot study
por: Taylor, K, et al.
Publicado: (2010)

Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?
por: Boyd, Kathleen A, et al.
Publicado: (2011)

Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial
por: Rodenhuis, S, et al.
Publicado: (2005)

IL-18-based combinatorial adjuvants promote the NK-DC-mediated production of the CCR7 ligand CCL19 in lymph nodes from cancer patients
por: Wong, Jeffrey L, et al.
Publicado: (2013)

Antigen-specific T lymphocyte responses elicited by a DNA – MVA HIV CN54gp140 immunization regime are significantly altered by the TLR4 adjuvant GLA
por: McKay, PF, et al.
Publicado: (2012)

The right ventricle in congenital heart disease - Cardiac T1 mapping for measurements of diffuse myocardial fibrosis
por: Al-Wakeel, Nadya, et al.
Publicado: (2016)

Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene
por: O'Connell, RJ, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8o6mblv6kovum06p983k1bpge1